Welcome to our dedicated page for Avenue Therapeutics news (Ticker: ATXI), a resource for investors and traders seeking the latest updates and insights on Avenue Therapeutics stock.
Avenue Therapeutics, Inc. (ATXI) generates a steady flow of news as a specialty pharmaceutical company focused on the development and commercialization of therapies for neurologic diseases. Company announcements highlight progress across its clinical pipeline, corporate transactions, financing activities, and stock listing matters, providing context for investors and followers of the neurologic drug development space.
News coverage commonly features clinical development updates for AJ201, Avenue’s first-in-class asset in development for spinal and bulbar muscular atrophy (SBMA). Releases describe milestones such as completion of last patient visits in a Phase 1b/2a trial, anticipated topline data timing, and details on trial design, endpoints, and biomarker strategies in SBMA, also known as Kennedy’s disease.
Another frequent topic is BAER-101, an oral small molecule selective GABAA α2, α3 receptor positive allosteric modulator for CNS diseases. Avenue has reported preclinical data demonstrating seizure suppression in epilepsy models, presented at scientific meetings and in peer-reviewed publications. Later news and SEC filings describe the acquisition of Avenue’s majority-owned subsidiary Baergic Bio, Inc. by Axsome Therapeutics, under which Axsome obtained worldwide rights to BAER-101 (AXS-17) and Avenue became eligible for potential milestone and royalty payments.
News items also address IV tramadol, including Avenue’s agreement with the U.S. Food and Drug Administration on a Phase 3 safety study protocol for acute postoperative pain in adults in a medically supervised setting. In addition, Avenue regularly reports on quarterly financial results, warrant exercise transactions, reverse stock split actions, participation in healthcare and investor conferences, and developments related to its stock exchange listing status.
Investors and observers who follow ATXI news can track how Avenue describes the evolution of its neurologic disease pipeline, its strategic transactions such as the Baergic/BAER-101 deal, and its efforts to secure financing and maintain public listing compliance. This news page brings together these company-issued updates in one place for ongoing reference.
Avenue Therapeutics, Inc. (Nasdaq: ATXI), a specialty pharmaceutical company focused on neurologic diseases, will present a corporate update at the Aegis Capital Virtual Conference on May 4, 2023, at 4:00 p.m. EDT. CEO Alexandra MacLean will lead the presentation. Interested participants can access the zoom link on Avenue's website for 30 days post-event. Avenue is developing three key assets: AJ201 for spinal and bulbar muscular atrophy, BAER-101 for CNS diseases, and IV Tramadol, currently in Phase 3 clinical development for pain management. Founded by Fortress Biotech, Avenue Therapeutics is headquartered in Miami, FL.
FAQ
What is the current stock price of Avenue Therapeutics (ATXI)?
What is the market cap of Avenue Therapeutics (ATXI)?
